Literature DB >> 24196894

[Psychotropic drugs in the Family Health Strategy: profile of use, access and strategies to promote rational use].

Bruno Simas da Rocha, Maria Cristina Werlang.   

Abstract

The use of psychotropic drugs is on the increase, and there are few studies in Brazil investigating their use in the population and in Primary Health Care (PHC). This study aimed to determine the prevalence and patterns of psychotropic drug use by patients of a Family Health Unit in Porto Alegre, through an observational, descriptive, retrospective and cross-sectional study. The sample consisted of patients who received prescriptions for controlled psychotropic drugs and the data collected from medical records. The study included 329 patients, with prevalence of the use of psychotropic drugs of 7.30%, mean age of 53.14 (SD = 18.58) years and 72% female. The average number of prescribed drugs and psychotropic drugs per user was 3.56 (SD = 2.36) and 1.66 (SD = 0.90), respectively. The most widely used class was antidepressants, followed by antiepileptics, anxiolytics and antipsychotics. It is necessary to develop strategies to improve access, treatment of patients and rational use of psychotropic drugs, including the revision of lists of essential drugs and training of professionals in PHC.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24196894     DOI: 10.1590/s1413-81232013001100019

Source DB:  PubMed          Journal:  Cien Saude Colet        ISSN: 1413-8123


  2 in total

1.  Why does mental health care not follow the structuring of primary care?

Authors:  Antonio Moacir de Jesus Lima; Eli Iola Gurgel Andrade; Antonio Thomaz Gonzaga da Matta Machado; Alainer de Fátima Dos Santos
Journal:  Rev Saude Publica       Date:  2021-12-08       Impact factor: 2.106

2.  Potentially inappropriate prescriptions for elderly people taking antidepressant: comparative tools.

Authors:  Izabela Fulone; Luciane Cruz Lopes
Journal:  BMC Geriatr       Date:  2017-12-02       Impact factor: 3.921

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.